CL2021000731A1 - Derivados de indano para uso en el tratamiento de infección bacteriana - Google Patents

Derivados de indano para uso en el tratamiento de infección bacteriana

Info

Publication number
CL2021000731A1
CL2021000731A1 CL2021000731A CL2021000731A CL2021000731A1 CL 2021000731 A1 CL2021000731 A1 CL 2021000731A1 CL 2021000731 A CL2021000731 A CL 2021000731A CL 2021000731 A CL2021000731 A CL 2021000731A CL 2021000731 A1 CL2021000731 A1 CL 2021000731A1
Authority
CL
Chile
Prior art keywords
treatment
bacterial infection
indane derivatives
indane
antibiotics
Prior art date
Application number
CL2021000731A
Other languages
English (en)
Inventor
Simon Leiris
David Thomas Davies
Martin Everett
Nicolas Sprynski
Lilha Beyria
Thomas David Pallin
Andrew Peter Cridland
Toby Jonathan Blench
Richard Leonard Elliott
David Edward Clark
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290106.6A external-priority patent/EP3628666A1/en
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of CL2021000731A1 publication Critical patent/CL2021000731A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)

Abstract

La invención se refiere a un compuesto que es un indano de acuerdo con la fórmula (I), o una sal farmacéuticamente aceptable del mismo, en donde R1, R2, R3, R4, R5, R6, n y p son como se definen en la presente. Los compuestos son útiles en el tratamiento de infección antibacteriana ya sea como antibióticos independientes o en combinación con antibióticos adicionales.
CL2021000731A 2018-09-25 2021-03-24 Derivados de indano para uso en el tratamiento de infección bacteriana CL2021000731A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18290106.6A EP3628666A1 (en) 2018-09-25 2018-09-25 Indane derivatives for use in the treatment of bacterial infection
EP18290104 2018-09-26
EP18197365 2018-09-27

Publications (1)

Publication Number Publication Date
CL2021000731A1 true CL2021000731A1 (es) 2021-11-05

Family

ID=67439236

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021000729A CL2021000729A1 (es) 2018-09-25 2021-03-24 Derivados de indano para el uso en el tratamiento de infección bacteriana
CL2021000731A CL2021000731A1 (es) 2018-09-25 2021-03-24 Derivados de indano para uso en el tratamiento de infección bacteriana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021000729A CL2021000729A1 (es) 2018-09-25 2021-03-24 Derivados de indano para el uso en el tratamiento de infección bacteriana

Country Status (14)

Country Link
US (2) US20210347748A1 (es)
EP (2) EP3856729A1 (es)
JP (2) JP7429992B2 (es)
KR (2) KR20210087025A (es)
CN (2) CN113166084B (es)
AU (2) AU2019351551A1 (es)
BR (2) BR112021005651A2 (es)
CA (2) CA3113689A1 (es)
CL (2) CL2021000729A1 (es)
IL (2) IL281770A (es)
MA (2) MA53706A (es)
MX (2) MX2021003498A (es)
SG (2) SG11202102791SA (es)
WO (2) WO2020064173A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7429992B2 (ja) * 2018-09-25 2024-02-09 アンタビオ エスアーエス 細菌感染の処置における使用のためのインダン誘導体
EP4125883A1 (en) * 2020-03-24 2023-02-08 Antabio SAS Combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JP3126541B2 (ja) * 1993-03-26 2001-01-22 千寿製薬株式会社 ベンゾチアゾール誘導体、その製法及びその用途
JPH0782259A (ja) * 1993-09-14 1995-03-28 Senju Pharmaceut Co Ltd スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤
JPH11130761A (ja) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
US7659300B2 (en) 2004-09-08 2010-02-09 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
FR2883876B1 (fr) 2005-03-30 2007-05-04 Servier Lab Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5028413B2 (ja) 2005-05-25 2012-09-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラン−ジオキサン誘導体類、および液晶媒体中におけるそれの使用
MX2009011615A (es) 2007-06-05 2009-11-10 Sanofi Aventis Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados.
EP2141164A1 (en) 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
EP2925137A1 (en) * 2012-11-30 2015-10-07 Bayer CropScience AG Binary fungicidal or pesticidal mixture
GB201704476D0 (en) * 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
JP7429992B2 (ja) 2018-09-25 2024-02-09 アンタビオ エスアーエス 細菌感染の処置における使用のためのインダン誘導体

Also Published As

Publication number Publication date
AU2019351551A1 (en) 2021-04-15
AU2019349438A1 (en) 2021-04-15
JP7429993B2 (ja) 2024-02-09
WO2020064174A1 (en) 2020-04-02
IL281770A (en) 2021-05-31
KR20210087025A (ko) 2021-07-09
CN113166084B (zh) 2024-06-04
MA53707A (fr) 2021-12-29
MA53706A (fr) 2021-12-29
SG11202102790PA (en) 2021-04-29
CN113166085B (zh) 2024-04-09
KR20210087448A (ko) 2021-07-12
BR112021005532A2 (pt) 2021-06-29
JP2022502485A (ja) 2022-01-11
JP2022502486A (ja) 2022-01-11
US20210347748A1 (en) 2021-11-11
BR112021005651A2 (pt) 2021-06-22
CN113166084A (zh) 2021-07-23
EP3856730A1 (en) 2021-08-04
IL281780A (en) 2021-05-31
EP3856729A1 (en) 2021-08-04
MX2021003485A (es) 2021-09-10
WO2020064173A1 (en) 2020-04-02
SG11202102791SA (en) 2021-04-29
JP7429992B2 (ja) 2024-02-09
US20220112169A1 (en) 2022-04-14
CA3113697A1 (en) 2020-04-02
CN113166085A (zh) 2021-07-23
MX2021003498A (es) 2021-09-10
CA3113689A1 (en) 2020-04-02
CL2021000729A1 (es) 2021-11-05

Similar Documents

Publication Publication Date Title
CO2022008091A2 (es) Inhibidores de kras g12c
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
ECSP18005828A (es) Inhibidores de metalo-beta-lactamasa
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CO2019005534A2 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CR20150183A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CL2021000731A1 (es) Derivados de indano para uso en el tratamiento de infección bacteriana
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CL2020001147A1 (es) Compuestos antibacterianos
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2020003248A1 (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas
ECSP22027871A (es) COMPUESTOS HETEROC?CLICOS DE ARILMETILENO COMO BLOQUEADORES DEL CANAL SHAKER DE POTASIO Kv1.3
BR112019002195A2 (pt) inibidores de beta-lactamase
CL2021003592A1 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos.
EA202190585A1 (ru) Производные индана для применения при лечении бактериальной инфекции
ES2506715A1 (es) Compuestos peptídicos útiles como agentes antibióticos
AR114260A2 (es) Sales y polimorfos de un compuesto de tetraciclina